Zosuquidar

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Zosuquidar
Zosuquidar.svg
Clinical data
ATC code
  • none
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard 100.236.552 Edit this at Wikidata
Chemical and physical data
Formula C32H31F2N3O2
Molar mass 527.61 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Zosuquidar (also LY-335979) is an experimental antineoplastic drug. In 2010, it was announced that a phase III trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome did not meet its primary endpoint[1] and Eli Lilly discontinued its development.

Zosquidir inhibits P-glycoproteins. Other drugs with this mechanism include tariquidar and laniquidar. P-glycoproteins are trans-membrane proteins that pump foreign substances out of cells in an ATP dependent fashion. Cancers overexpressing P-glycoproteins are able to pump out therapeutic molecules before they are able to reach their target, effectively making the cancer multi-drug resistant. Zosuquidar inhibits P-glycoproteins, inhibiting the efflux pump and restoring sensitivity to chemotherapeutic agents.

Zosuqidar was initially characterized by Syntex Corporation, which was acquired by Roche in 1990. Roche licensed the drug to Eli Lilly in 1997. It was granted orphan drug status by the FDA in 2006 for AML.

References[edit]